Details of the Chinese instructions for Cabozantinib

1. Overview of basic drug information

Cabozantinib (Cabozantinib) is an oral small molecule multi-target tyrosine kinase inhibitor that mainly works by inhibiting multiple signaling pathways related to tumor growth, invasion and angiogenesis. This drug was used early in the field of overseas tumor treatment, covering a variety of solid tumor types, and is a typical multi-pathway targeted anti-tumor drug. At the drug management level, cabozantinib is available in two different dosage forms: capsules and tablets, with clear distinctions in indications and medication regimens

2. Description of indication scope

1. The capsule dosage form is mainly used to treat progressive or metastatic medullary thyroid cancer. This type of tumor usually has limited sensitivity to traditional radiotherapy or chemotherapy.

2. The tablet dosage form is suitable for a variety of solid tumors, including advanced renal cell carcinoma (RCC). It can be used as a single drug treatment or in combination with immunotherapy regimens

1) In patients with hepatocellular carcinoma (HCC) who have progressed after previous systemic therapy, cabozantinib tablets are used as one of the subsequent treatment options;

2) Cabozantinib has certain application value for patients with locally advanced or metastatic differentiated thyroid cancer, especially those who have failed previous VEGFR targeted therapy and are not suitable for radioactive iodine therapy.

3) In unresectable well-differentiated pancreatic neuroendocrine tumors and extrapancreatic neuroendocrine tumors, cabozantinib has also been included in systemic treatment plans.

3. Core interpretation of usage and dosage

Capsule dosage form is usually taken once a day for the treatment of medullary thyroid cancer, and the principle of fasting must be strictly adhered to. Tablets can be used alone in renal cell carcinoma, or in combination with immunological drugs such as nivolumab. The dosage setting under the combination regimen is different from that of the single drug regimen. In the treatment of hepatocellular carcinoma and differentiated thyroid cancer, tablets are mostly administered once a day, emphasizing continuity and regularity. When using the drug in children and adolescent patients, it is necessary to combine body surface area assessment to ensure that the dose matches individual tolerance.

It is important to emphasize that cabozantinib capsules and tablets are not interchangeable, and they cannot be used interchangeably even if they have the same ingredients.

4. Medication precautions and management points

Cabozantinib is more sensitive to eating status, and it is usually recommended to take it one hour before or two hours after a meal to reduce absorption fluctuations.

Dosage adjustments need to be made under the guidance of a doctor during the treatment process, especially when tolerance problems occur, timely evaluation should be carried out

The patient's overall condition should be monitored regularly during medication, including gastrointestinal reactions, skin changes, and blood pressure changes, etc.

For patients who need to take long-term medication, standardized follow-up can help improve medication safety and treatment continuity.

5. Overall evaluation of drug use

Judging from overseas instructions and actual drug use experience, the advantage of cabozantinib lies in the synergistic inhibition of multiple targets and is suitable for a variety of tumor types.

Different dosage forms correspond to different disease spectrums. Reasonable selection of dosage forms and dosages is an important prerequisite for exerting curative effect.

For patients, fully understanding the key points of the instructions can help improve treatment compliance and reduce unnecessary medication risks.

Keyword tags:

Chinese instructions for cabozantinib,Cabozantinib usage and dosage, cabozantinib indications, differences between cabozantinib capsules and tablets, renal cell carcinoma targeted drugs, hepatocellular carcinoma treatment options, thyroid cancer targeted therapy, neuroendocrine tumor drugs

Reference materials:https://www.medicines.org.uk/emc/product/15682/smpc